* Corcept Therapeutics Inc reported quarterly adjusted earnings of 41 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of 28 cents. The mean expectation of five analysts for the quarter was for earnings of 28 cents per share. Wall Street expected results to range from 25 cents to 34 cents per share.

* Revenue rose 47.7% to $182.55 million from a year ago; analysts expected $171.97 million.

* Corcept Therapeutics Inc's reported EPS for the quarter was 41 cents​.

* The company reported quarterly net income of $47.21 million.

* Corcept Therapeutics Inc shares had risen by 4.2% this quarter and gained 48.4% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 2.9% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Corcept Therapeutics Inc is $76.00 This summary was machine generated from LSEG data October 31 at 02:35 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 0.28 0.41 Beat

Jun. 30 2024 0.23 0.32 Beat

Mar. 31 2024 0.22 0.25 Beat

Dec. 31 2023 0.26 0.28 Beat